AstraZeneca Sues to Block Copies of Tagrisso Cancer Drug

AstraZeneca said proposed generic versions of a lung cancer treatment by Alembic, MSN Labs and Zydus Cadila infringe a patent for Tagrisso.

• AstraZeneca is seeking a court order blocking copies until the patent has expired, according to complaint filed Tuesday in federal court in Wilmington, Delaware
• Patent was issued in January 2019, complaint says; it expires in January 2035, according to supplemental filing
• Tagrisso had U.S. sales of $909 million during the first nine months of 2019, 57% more than during the same period a year earlier, AstraZeneca said Oct. 24 in its quarterly earnings report
• NOTE: Tagrisso Has ...